Autologous cell therapy market surpasses $10.1 billion in 2025, fueled by gene editing and biotech advancements.

The autologous cell therapy market reached $10.1 billion in 2025, with biotech companies racing to develop therapies for age-related diseases and metabolic disorders. Cell harvesting infrastructure expanded to support next-generation manufacturing, driving momentum across platforms. Publicly traded companies at the intersection of cell engineering, protein delivery, and precision medicine are gaining attention, including Avant Technologies, Sana Biotechnology, Lineage Cell Therapeutics, and CRISPR Therapeutics.